PetMedix

Antibody Innovation in Animal Health

PetMedix is using the highest quality science to make the medicines our pets need and deserve, keeping them healthier, happier, and for longer.

About the Company

PetMedix is using the highest quality science to make the medicines our pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human therapeutic drug development, we are applying the cutting edge of science to bring breakthroughs for the animals we love and care for.

The bond we have with our dogs and cats is a special one, they share our homes and are such an important part of our lives. Unfortunately, they also share our health problems, and can suffer from many of the same diseases and conditions we do. Whilst it is possible to give some types of human medicines to pets, it is not possible to do it with therapeutic antibodies – the pet immune systems would reject them. What this means is that there are all of these conditions, such as cancer, allergy, arthritis, and many more, that we can successfully treat in people but where our pets are suffering needlessly.

PetMedix is taking the experience of its founding team, and decades of human clinical research, to build platforms that can develop fully species-specific, naturally-generated therapeutic antibodies.  We will use these platforms to develop our own veterinary medicines to target some of the most important underserved clinical areas, which not only would have critical healthcare impact, but also represent excellent market opportunities.

Animal Pharm Award Winner 2019
The Spinoff Prize - One to watch 2020

PetMedix are proud to have been voted ‘Best Start-Up 2019’ in the Animal Pharm Awards and ‘One to Watch’ in the Nature Spinoff Awards 2020.

Our History

March 2014
PetMedix founder, Prof Allan Bradley FRS, publishes complete humanization of the mouse immunoglobulin locus in Nature
November 2017
Completion of PhD project adapting the transgenic platform from human to canine at Wellcome Sanger Institute
January 2019
Size of company: 12 staff
February 2019
Shortlisted to present at the Animal Health Investment Europe Innovation Showcase
August 2019
Presented at Kansas City Investment Forum on future solutions for pet health
January 2020
Size of company: 24 staff
April 2020
Move to Babraham Research Campus
June 2020
Judged as ‘One to Watch’ in the global Nature Spinoff Awards
November 2020
Dr Amy Li, PetMedix’s head of Research and Innovation named in Movers and Shakers in BioBusiness 2020 report
September 2017
PetMedix founder, Dr Jolyon Martin, publishes first comprehensive annotation of canine immunoglobulin loci in Immunogenetics
January 2018
Formation of PetMedix as a company
February 2019
£8million series A funding secured
April 2019
Dr Fabian Kausche and Dr Cindy Cole join the Board of Directors
December 2019
Dr Dave Lowery joins the company
February 2020
Animal Pharm 'Best Start-up 2019' award winner
May 2020
Funding from Cambridge Innovation Capital secured
October 2020
Size of company: 32 staff
handshake
January 2021
PetMedix enters into partnership with Boehringer Ingelheim
March 2014
PetMedix founder, Prof Allan Bradley FRS, publishes complete humanization of the mouse immunoglobulin locus in Nature
September 2017
PetMedix founder, Dr Jolyon Martin, publishes first comprehensive annotation of canine immunoglobulin loci in Immunogenetics
November 2017
Completion of PhD project adapting the transgenic platform from human to canine at Wellcome Sanger Institute
January 2018
Formation of PetMedix as a company
January 2019
Size of company: 12 staff
February 2019
£8million series A funding secured
February 2019
Shortlisted to present at the Animal Health Investment Europe Innovation Showcase
April 2019
Dr Fabian Kausche and Dr Cindy Cole join the Board of Directors
August 2019
Presented at Kansas City Investment Forum on future solutions for pet health
December 2019
Dr Dave Lowery joins the company
January 2020
Size of company: 24 staff
February 2020
Animal Pharm 'Best Start-up 2019' award winner
April 2020
Move to Babraham Research Campus
May 2020
Funding from Cambridge Innovation Capital secured
June 2020
Judged as ‘One to Watch’ in the global Nature Spinoff Awards
October 2020
Size of company: 32 staff
November 2020
Dr Amy Li, PetMedix’s head of Research and Innovation named in Movers and Shakers in BioBusiness 2020 report
handshake
January 2021
PetMedix enters into partnership with Boehringer Ingelheim

Our Leadership Team

Head of Product & Business Development

PetMedix is recruiting, see our careers page for more information

Scroll to Top